PSNL Earnings

Personalis Reports Second Quarter 2025 Financial Results

Published August 05, 2025 at 08:01 PM

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal®

Related Questions

What is the net revenue growth rate year-over-year for Q2 2025 and how does it compare to analyst expectations? What is the forward-looking guidance for revenue and earnings in the next quarter and FY 2025? What is the contribution margin and overall profitability of the NeXT Personal® platform in Q2 2025? What were the underlying drivers of the increase in clinical test volume (e.g., new contracts, pricing changes, new product adoption)? How does the Q2 2025 cash burn and cash runway compare to prior quarters and what is the updated cash runway outlook? How does the 59% sequential increase in clinical tests compare to prior quarters and to the company's historical growth rates? How have recent macro‑economic factors (e.g., reimbursement policy changes, healthcare spending trends) impacted the outlook? What is the expected impact of potential dilution from future equity issuances or convertible debt? What technical or competitive risks could affect the sustainability of the 59% test volume growth? What is the status of the “Win‑in‑MRD” strategy and its potential impact on future market share and pricing power? Are there any regulatory approvals, FDA clearances or reimbursement updates that could affect future revenue? How does Personalis’ performance compare with other precision oncology and genomics companies (e.g., Illumina, Guardant Health, Invitae) in terms of test volume and revenue growth? What are the trends in operating expenses, R&D and SG&A, and how are they impacting profitability? What guidance does management provide regarding the timeline and scalability of the NeXT Personal® platform? What is the composition of the customer base (e.g., number of hospital/clinical partners) and its concentration risk? What are the anticipated impacts of any recent partnership or licensing agreements on future revenue and margins? What is the current level of GAAP and non‑GAAP earnings per share, and how do they compare to consensus estimates?